business news in context, analysis with attitude

The Washington Post reports that the US Senate yesterday, in a largely bipartisan vote, confirmed Stephen Hahn to be the new commissioner of the US Food and Drug Administration (FDA), taking over an organization that is juggling issues ranging from underage vaping to the import of cheaper drugs from Canada, from CBD to "unapproved treatments by commercial stem cell clinics."

According to the story, "Hahn, a researcher as well as a medical and radiation oncologist, has most recently been chief medical executive at MD Anderson in Houston, responsible for the cancer center’s clinical care." He is the first permanent FDA commissioner since the resignation of Scott Gottlieb last spring.
KC's View: